Mesoblast (MESO) Reports Q2 Loss of $0.06

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. SPY
3. GLOB
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Mesoblast (MESO) Reports Q2 Loss of $0.06

Mesoblast Reports on First Half and Second Quarter Financial Results

February 16, 2016 4:41 PM EST

MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB) (Nasdaq: MESO) today reported financial results and operational highlights for the 1H/2Q ended 31 December 2015.

Financial Highlights (USD)

At 31 December 2015, the Company had cash reserves of $120.8 million. 

Operating cash outflow for the second quarter of 2016 was US$19.8 million, a reduction of over 25% in comparison to the first quarter of 2016 (US$28.1 million) and the fourth quarter of 2015 (US$27.3 million).  This reduction was... More

Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis

February 16, 2016 6:00 AM EST

NEW YORK and MELBOURNE, Australia, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB) (Nasdaq: MESO) today announced results from the first cohort of its ongoing Phase 2 trial in rheumatoid arthritis (RA) patients who have previously failed one or more biologic agents. Top line results showed that a single intravenous infusion of the lower dose of Mesoblasts proprietary Mesenchymal Precursor Cell (MPC) product candidate, MPC-300-IV, was safe and resulted in early and... More